Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1162-1167

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mousa, S. A.
Right arrow Articles by Forsythe, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mousa, S. A.
Right arrow Articles by Forsythe, M. S.
Related Collections
Right arrow Platelets
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1162.)
© 2000 American Heart Association, Inc.

Thrombosis

Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography

Differentiation Among Glycoprotein IIb/IIIa Antagonists

Shaker A. Mousa; Sandeep Khurana; Mark S. Forsythe

From DuPont Pharmaceuticals Co (S.A.M., M.S.F.), Wilmington, Del, and William Beaumont Hospital (S.K.), Royal Oak, Mich.

Correspondence to Shaker A. Mousa, PhD, FACC, DuPont Pharmaceuticals Co, 141 and Henry Clay Road, Exp. Station, E400/3470, Wilmington, DE 19880-0400. E-mail shaker.a.mousa{at}dupontpharma.com

Abstract—In the present study, the in vitro efficacy of different platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on platelet-fibrin–mediated clot strength under shear was compared with the antiaggregatory efficacy by using tissue factor (TF) thromboelastography (TEG). The ability of platelets to augment the elastic properties of blood clots under shear conditions was measured by computerized TEG under conditions of maximal platelet activation accelerated by recombinant TF. Under these conditions, platelets significantly enhance clot strength 8-fold (relative to platelet-free fibrin clots). This effect was inhibited to a different extent by various platelet GPIIb/IIIa receptor antagonists; this inhibition appears to be dependent on the transmission of platelet contractile force to fibrin via the GPIIb/IIIa receptors. The GPIIb/IIIa antagonists with high binding affinity for resting and activated platelets and slow platelet dissociation rates (class I) but not those with fast platelet dissociation rates (class II) demonstrated potent and comparable inhibition of platelet aggregation and TF-TEG clot strength. Platelet GPIIb/IIIa antagonists of class I, such as XV459 (free-acid form of roxifiban), DMP802, XV454, and c7E3, demonstrated comparable inhibitory dose responses of TF-TEG clot strength and platelet aggregation, with an IC50 of 50 to 70 nmol/L. In contrast, platelet GPIIb/IIIa antagonists from class II, with comparable antiaggregatory efficacy, such as DMP728, YZ202 (free-acid form of orbofiban), YZ211 (free-acid form of sibrafiban), YZ751, and other antagonists, have a much lower efficacy in altering the strength of TF-mediated clot formation (IC50 >1.0 µmol/L). These data suggest differential efficacy among different GPIIb/IIIa antagonists in inhibiting platelet-fibrin clot retraction despite of equivalent antiaggregatory potency.


Key Words: platelet glycoprotein IIb/IIIa antagonists • binding kinetics • integrins • tissue factor • thromboelastography




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
N. Katori, F. Szlam, J. H. Levy, and K. A. Tanaka
A Novel Method to Assess Platelet Inhibition by Eptifibatide with Thrombelastograph(R)
Anesth. Analg., December 1, 2004; 99(6): 1794 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G.A. Stouffer and S.S. Smyth
Effects of Thrombin on Interactions Between {beta}3-Integrins and Extracellular Matrix in Platelets and Vascular Cells
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1971 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Wang, R. T. Dorsam, A. Lauver, H. Wang, F. A. Barbera, S. Gibbs, D. Varon, N. Savion, S. M. Friedman, and G. Z. Feuerstein
Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion
J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1114 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes
Circulation, April 3, 2001; 103(13): 1727 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos
Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis
Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 149 - 156.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. P. Cannon, C. H. McCabe, R. G. Wilcox, A. Langer, A. Caspi, P. Berink, J. Lopez-Sendon, J. Toman, A. Charlesworth, R. J. Anders, et al.
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
Circulation, July 11, 2000; 102(2): 149 - 156.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.